RCM
RA Capital Management Portfolio holdings
AUM
$5.94B
This Quarter Return
+1.1%
1 Year Return
+18.15%
3 Year Return
+417.5%
5 Year Return
+458.13%
10 Year Return
+21,247.51%
AUM
$3.17B
AUM Growth
+$3.17B
(-4%)
Cap. Flow
+$189M
Cap. Flow
% of AUM
5.98%
Top 10 Holdings %
Top 10 Hldgs %
55.39%
Holding
52
New
18
Increased
15
Reduced
4
Closed
4
Top Buys
| 1 |
Axsome Therapeutics
AXSM
|
$90.4M |
| 2 |
Ascendis Pharma
ASND
|
$82.2M |
| 3 |
Exelixis
EXEL
|
$77.9M |
| 4 |
Alector
ALEC
|
$75.5M |
| 5 |
ZGNX
Zogenix, Inc.
ZGNX
|
$74.6M |
Top Sells
Sector Composition
| 1 | Healthcare | 93.27% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
1
Ascendis Pharma
ASND
$11.8B
| $553M | 17.48% | 4,914,955 +729,613 | +17% | +$82.2M |
|
|
RARX
2
DELISTED
Ra Pharmaceuticals, Inc. Common Stock
RARX
| $233M | 7.37% | 4,858,260 | – | – |
|
|
CCXI
3
DELISTED
ChemoCentryx, Inc.
CCXI
| $168M | 5.3% | 4,176,910 +977,521 | +31% | +$39.3M |
|
4
Arvinas
ARVN
$568M
| $148M | 4.68% | 3,672,872 | – | – |
|
|
ZGNX
5
DELISTED
Zogenix, Inc.
ZGNX
| $130M | 4.12% | 5,275,538 +3,014,787 | +133% | +$74.6M |
|
|
6
Axsome Therapeutics
AXSM
$6.05B
| $112M | 3.54% | 1,904,094 +1,536,278 | +418% | +$90.4M |
|
|
EIDX
7
DELISTED
Eidos Therapeutics, Inc. Common Stock
EIDX
| $106M | 3.35% | 2,162,671 | – | – |
|
8
TG Therapeutics
TGTX
$4.65B
| $102M | 3.23% | 10,387,411 +507,088 | +5% | +$4.99M |
|
|
STSA
9
DELISTED
Satsuma Pharmaceuticals, Inc. Common Stock
STSA
| $101M | 3.18% | 4,681,858 | – | – |
|
|
10
Alector
ALEC
$238M
| $99.6M | 3.15% | 4,127,348 +3,127,348 | +313% | +$75.5M |
|
11
Phathom Pharmaceuticals
PHAT
$864M
| $95.7M | 3.02% | 3,707,408 +60,600 | +2% | +$1.56M |
|
12
KALA BIO
KALA
$78.8M
| $95.6M | 3.02% | 10,874,613 +6,337,135 | +140% | +$55.7M |
|
13
Rhythm Pharmaceuticals
RYTM
$6.85B
| $82.5M | 2.61% | 5,422,312 | – | – |
|
14
89bio
ETNB
$1.34B
| $79.8M | 2.52% | 3,161,214 | – | – |
|
|
15
Exelixis
EXEL
$10.1B
| $77.9M | 2.46% | +4,524,961 | New | +$77.9M |
|
16
Wave Life Sciences
WVE
$1.53B
| $72.9M | 2.3% | 7,775,207 | – | – |
|
17
Adverum Biotechnologies
ADVM
$64.6M
| $71.1M | 2.24% | +7,272,714 | New | +$71.1M |
|
|
MNTA
18
DELISTED
Momenta Pharmaceuticals, Inc.
MNTA
| $68.9M | 2.18% | 2,531,445 +1,085,644 | +75% | +$29.5M |
|
19
Black Diamond Therapeutics
BDTX
$157M
| $64.6M | 2.04% | +2,589,904 | New | +$64.6M |
|
20
Travere Therapeutics
TVTX
$1.56B
| $60.8M | 1.92% | 4,166,453 -86,000 | -2% | -$1.25M |
|
|
ORTX
21
DELISTED
Orchard Therapeutics plc American Depositary Shares
ORTX
| $57M | 1.8% | 10,364,658 +3,974,757 | +62% | +$21.9M |
|
|
IGMS
22
DELISTED
IGM Biosciences
IGMS
| $55.2M | 1.74% | 982,723 | – | – |
|
23
Verastem
VSTM
$569M
| $49.1M | 1.55% | +18,604,651 | New | +$49.1M |
|
24
Relmada Therapeutics
RLMD
$37.2M
| $47.1M | 1.49% | 1,379,988 +618,322 | +81% | +$21.1M |
|
25
Gilead Sciences
GILD
$140B
| $41M | 1.29% | +548,000 | New | +$41M |
|